Trials / Completed
CompletedNCT01856426
Proof of Concept Study for Safety and Efficacy of EDP239 in Hepatitis C Subjects
Double-Blind, Randomized, Placebo-controlled, Multi-center Trial to Determine the Safety and Antiviral Effect of Single Doses of EDP239 in Hepatitis C Virus (HCV) Infected Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Enanta Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is, to assess whether EDP239 can reduce the HCV viral load in HCV gentotype-1 in chronically infected subjects and to further evaluate the safety profile of EDP239.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | EDP239 | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-06-01
- Primary completion
- 2014-11-01
- Completion
- 2015-10-01
- First posted
- 2013-05-17
- Last updated
- 2016-01-29
Locations
5 sites across 2 countries: United States, Germany
Source: ClinicalTrials.gov record NCT01856426. Inclusion in this directory is not an endorsement.